| Identification | Back Directory | [Name]
1-Piperazineethanol, 4-[2-[[bis(4-fluorophenyl)methyl]thio]ethyl]-α-methyl- | [CAS]
1627576-64-0 | [Synonyms]
1-Piperazineethanol, 4-[2-[[bis(4-fluorophenyl)methyl]thio]ethyl]-α-methyl- | [Molecular Formula]
C22H28F2N2OS | [MOL File]
1627576-64-0.mol | [Molecular Weight]
406.53 |
| Chemical Properties | Back Directory | [Melting point ]
205-206 °C | [Boiling point ]
521.3±50.0 °C(predicted) | [density ]
1.190±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
15.03±0.20(predicted) |
| Hazard Information | Back Directory | [Uses]
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. [1][2]. | [References]
[1] Ecevitoglu A, et al. Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors. Neuropsychopharmacology. 2024 Mar 1. DOI:10.1038/s41386-024-01826-1
[2] Tunstall BJ, et al. Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats. Neuropharmacology. 2018 Mar 15;131:96-103. DOI:10.1016/j.neuropharm.2017.12.006 |
|
|